Analogues of the drug Afobazole indications for use and benefits

The content of the article:
  1. Nosology
  2. CAS code
  3. Substance characteristics
  4. Pharmacodynamics
  5. Indications for use
  6. contraindications
  7. Restrictions on use
  8. Application in pregnancy and lactation
  9. S >From the nervous system and sensory organs. Fatigue. Weakness. Dizziness. Headache. Drowsiness or insomnia. Nightmares. Depression. Anxiety. Confusion or short-term memory loss. Hallucinations. Weakening reactivity. Paresthesia Cramps visual impairment. Decreased secretion of saliva and tear fluid. Conjunctivitis. From the cardiovascular system and blood (hematopoiesis. Hemostasis): bradycardia. Heartbeat Violation of myocardial conduction. AV block. Arrhythmias. Weakening myocardial contractility. Heart failure. Hypotension. Syncope. Raynaud’s phenomenon. Vasculitis. Chest pain. Thrombocytopenia. Agranulocytosis. From the digestive tract. Dry mouth, nausea, vomiting, abdominal pain, diarrhea, constipation, impaired liver function. From the respiratory system. Shortness of breath, laryngo – and bronchospasm. Allergic reactions. Itching, rash, erythema, urticaria, psoriasis-like and dystrophic skin changes. Other. Reversible Alopecia. Hyperhidrosis. Coldness of limbs. Myasthenia gravis Weakening libido. Impotence. Peyronie’s disease. Change in enzyme activity. Bilirubin level. Withdrawal syndrome. Hypothyroid state. Hypoglycemia.
  10. Interaction
  11. Overdose
  12. Dosing and Administration
  13. Application Precautions
  14. Pharmacodynamics
  15. Indications for use
  16. Nosology
  17. Substance characteristics
  18. Dosing and Administration
  19. Interaction
  20. Overdose
  21. When is it taken and compatible with other medicines?
  22. Application Precautions

Nosology

• E05,9 Thyrotoxicosis, unspecified.
• G25,0 Essential tremor.
• G43 Migraine.
• I10 Essential (primary) hypertension.
• I15 Secondary hypertension.
• I20 Angina pectoris [angina pectoris].
• I20,0 Unstable angina pectoris.
• I21 Acute myocardial infarction.
• I25 Chronic ischemic heart disease.
• I25,2 Past myocardial infarction.
• I27 Other forms of pulmonary heart disease.
• I34,1 Mitral valve prolapse.
• I42 Cardiomyopathy.
• I47,1 Supraventricular tachycardia.
• I47,2 Ventricular tachycardia.
• I48 Atrial fibrillation and flutter.
• I49,4 Other and unspecified premature depolarization.
• I49,9 Unspecified heart rhythm disorder.
• R07,2 Pain in the region of the heart.

CAS code

Substance characteristics

Crystalline powder. Soluble in water (26,5 mg / ml at 37 ° C), good in 1M hydrochloric acid solution (300 mg / ml at 25 ° C) and poorly in chloroform (3 mg / ml at temperature 25 ° C).

Pharmacodynamics

Pharmacological action – antianginal, hypotensive, antiarrhythmic.
Selectively blocks beta1-adrenergic receptors, does not have membrane-stabilizing and internal sympathomimetic activity. It inhibits central sympathetic impulse, weakens the sensitivity of peripheral tissues to catecholamines, and inhibits renin secretion. Trims heart rate at rest and during physical exertion. A negative chronotropic effect appears after 1 h, reaches a maximum after 2–4 h, lasts up to 24. Reduces cardiac output, blood pressure and blood pressure, reduces orthostatic tachycardia. The antihypertensive effect lasts 24 hours, stabilizes with regular admission by the end of 2 weeks. Reduces myocardial oxygen demand, but due to an increase in the tension of the muscle fibers of the ventricles and the final diastolic pressure in the left ventricle, it can increase oxygen demand, especially in patients with chronic heart failure. It suppresses the automatism of the sinus node, lengthens the refractory period, and slows down the AV node. Increases the survival of patients after myocardial infarction (lowers the frequency of ventricular arrhythmias and angina attacks). Slightly reduces the vital function of the lungs, practically does not weaken the bronchodilating effect of isoproterenol.
After oral administration, about 50% is absorbed, in the elderly – slightly more. Cmax is reached after 2–4 hours, binding to plasma proteins – 6–16%. It penetrates poorly through the BBB, passes through the placental barrier and into breast milk. Almost not metabolized in the liver, excreted by the kidneys by glomerular filtration (85%). T1 / 2 – 6-7 hours, increases in elderly patients. Impaired renal function is accompanied by an extension of T1 / 2 and cumulation: the ability to cumulate is manifested when creatinine Cl is below 35 ml / min / 1,73 m2 (dose reduction is necessary).
Long-term use is accompanied by vacuolization of the duodenal epithelium in dogs (15 mg / kg / day) and the development of degenerative processes in the myocardium of male rats (300 mg / kg / day). In experiments on rats (18 months) and mice (24 months) at a dose of 300 mg / kg / day, it has no carcinogenic effect. At doses of 500 and 1500 mg / kg / day (rats), it increases the incidence of benign tumors of the adrenal medulla, adenomas of the anterior pituitary, breast fibroadenomas (females), and parafollicular cell carcinoma of the thyroid gland (males). The cytogenetic test (in vivo) and the Ames test did not reveal mutagenic properties. In males and females of rats, doses 100 times higher than the MPDF did not adversely affect fertility. At a dose of 50 mg / kg / day, the incidence of resorption of the embryo / fetus in rats increases.

Indications for use

Arterial hypertension. Angina pectoris. Acute myocardial infarction (with stable hemodynamics). Tachycardia: sinus. Atrial Ventricular. Paroxysmal and so on; Extrasystole. Atrial flutter and flickering. Hyperkinetic cardiac syndrome. Mitral valve prolapse. Hypertensive neurocirculatory dystonia; complex therapy of hypertrophic cardiomyopathy. Pheochromocytomas. Thyrotoxicosis. Essential tremor; migraine (prevention).

contraindications

Hypersensitivity, sinus bradycardia (heart rate less than 50 beats / min), sinoatrial blockade, sinus node weakness syndrome, AV block II – III degree, arterial hypotension (with arterial pressure less than 90 mm), acute or chronic heart failure in the decompensation stage, cardiogenic shock, peripheral circulation disorder, pregnancy, breast-feeding.

Restrictions on use

Diabetes mellitus, hypoglycemia, chronic obstructive pulmonary diseases (emphysema, bronchial asthma), impaired liver and / or kidney function, myasthenia gravis, depression, psoriasis, pheochromocytoma, metabolic acidosis, pediatric (efficacy and safety not determined) and old age.

Application in pregnancy and lactation

FDA category of action on the fetus. D.
For the duration of treatment, breastfeeding should be discontinued.

S >From the nervous system and sensory organs. Fatigue. Weakness. Dizziness. Headache. Drowsiness or insomnia. Nightmares. Depression. Anxiety. Confusion or short-term memory loss. Hallucinations. Weakening reactivity. Paresthesia Cramps visual impairment. Decreased secretion of saliva and tear fluid. Conjunctivitis.
From the cardiovascular system and blood (hematopoiesis. Hemostasis): bradycardia. Heartbeat Violation of myocardial conduction. AV block. Arrhythmias. Weakening myocardial contractility. Heart failure. Hypotension. Syncope. Raynaud’s phenomenon. Vasculitis. Chest pain. Thrombocytopenia. Agranulocytosis.
From the digestive tract. Dry mouth, nausea, vomiting, abdominal pain, diarrhea, constipation, impaired liver function.
From the respiratory system. Shortness of breath, laryngo – and bronchospasm.
Allergic reactions. Itching, rash, erythema, urticaria, psoriasis-like and dystrophic skin changes.
Other. Reversible Alopecia. Hyperhidrosis. Coldness of limbs. Myasthenia gravis Weakening libido. Impotence. Peyronie’s disease. Change in enzyme activity. Bilirubin level. Withdrawal syndrome. Hypothyroid state. Hypoglycemia.

Interaction

Antiarrhythmic and anesthetic drugs enhance cardiodepressive effect (the risk of developing bradycardia, arrhythmias, hypotension, heart failure). Reserpine, methyldopa, clonidine, guanfacine, cardiac glycosides potentiate the negative chrono-, dromo- and batmotropic effect, insulin and other antidiabetic agents – hypoglycemia. NSAIDs, estrogens, sympathomimetics, xanthines weaken the hypotensive effect, absorption, increase – sympatholytics, nitroglycerin, hydralazine and other antihypertensive drugs, antacids – slow down absorption. Cimetidine inhibits metabolism. It prolongs the action of antidepolarizing muscle relaxants, the anticoagulant effect of coumarins. Three / tetracyclic antidepressants, antipsychotics, sedatives, hypnotics and alcohol potentiate CNS depression. Incompatible with MAO inhibitors.

Overdose

Symptoms Bradycardia, AV – blockade II – III degree, heart failure, respiratory failure, hypotension, bronchospasm, hypoglycemia.
Treatment. Gastric lavage and the appointment of adsorbing agents; symptomatic therapy is atropine. Isoprenaline. Orciprenaline. Cardiac glycosides or glucagon. Diuretics. Vasopressor drugs (dopamine. Dobutamine or norepinephrine). Selective beta-adrenergic agonists. Glucose solution (w / w). Installing an artificial pacemaker. Dialysis is possible.

Dosing and Administration

Application Precautions

Treatment is carried out with regular medical supervision. Before starting therapy, heart failure should be compensated. During treatment, monitoring of heart rate, blood pressure, blood glucose level (dose adjustment of antidiabetic drugs is possible) and monitoring of the appearance of symptoms of heart failure are necessary.
Use with caution while working for drivers of vehicles and people whose profession is associated with increased concentration of attention. At the time of therapy, it is recommended to exclude alcohol intake.
In patients with diabetes mellitus and hyperthyroidism, it can mask tachycardia caused by hypoglycemia or thyrotoxicosis. With pheochromocytoma, alpha-adrenolytics should be used simultaneously. It is possible to increase the severity of the hypersensitivity reaction and the lack of effect of the usual doses of epinephrine against the background of a burdened allergic history.
In case of increasing bradycardia (less than 50 beats / min) in patients of advanced age, hypotension (with arterial pressure below 100 mm), AV block, bronchospasm, ventricular arrhythmias, severe liver and kidney dysfunctions, it is necessary to reduce the dose or stop treatment. The therapy should be discontinued gradually, reducing the dose, within 10-14 days. Patients with coronary heart disease should be closely monitored during the period of drug withdrawal. Atenolol should be discontinued 48 hours before surgery using general anesthesia (chloroform or ether) or choose an anesthetic with the least negative inotropic effect.

Pharmacodynamics

Pharmacological action – antianginal, hypotensive, antiarrhythmic. Selectively blocks beta1-adrenergic receptors, does not have membrane-stabilizing and internal sympathomimetic activity. It inhibits central sympathetic impulse, weakens the sensitivity of peripheral tissues to catecholamines, and inhibits renin secretion.

Trims heart rate at rest and during physical exertion. A negative chronotropic effect appears after 1 h, reaches a maximum after 2–4 h, lasts up to 24. Reduces cardiac output, blood pressure and blood pressure, reduces orthostatic tachycardia. The antihypertensive effect lasts 24 hours, stabilizes with regular admission by the end of 2 weeks.

Reduces myocardial oxygen demand, but due to an increase in the tension of the muscle fibers of the ventricles and the final diastolic pressure in the left ventricle, it can increase oxygen demand, especially in patients with chronic heart failure. It suppresses the automatism of the sinus node, lengthens the refractory period, and slows down the AV node.

Increases the survival of patients after myocardial infarction (lowers the frequency of ventricular arrhythmias and angina attacks). Slightly reduces the vital function of the lungs, practically does not weaken the bronchodilating effect of isoproterenol. After oral administration, about 50% is absorbed, in the elderly – slightly more.

the ability to cumulate is manifested with Cl creatinine below 35 ml / min / 1,73 m2 (dose reduction is necessary). Long-term use is accompanied by vacuolization of the duodenal epithelium in dogs (15 mg / kg / day) and the development of degenerative processes in the myocardium of male rats (300 mg / kg / day). In experiments on rats (18 months) and mice (24 months) at a dose of 300 mg / kg / day, it has no carcinogenic effect.

At doses of 500 and 1500 mg / kg / day (rats), it increases the incidence of benign tumors of the adrenal medulla, adenomas of the anterior pituitary, breast fibroadenomas (females), and parafollicular cell carcinoma of the thyroid gland (males). The cytogenetic test (in vivo) and the Ames test did not reveal mutagenic properties.

Active substance: fabomotizole (fabomotizole dihydrochloride) – 5 mg and 10 mg. Excipients: potato starch – 48 mg, microcrystalline cellulose – 40 mg (for a dosage of 5 mg) and 35 mg (for a dosage of 10 mg), lactose monohydrate – 48,5 mg, medium molecular weight povidone (medical average molecular weight polyvinylpyrrolidone, collidone 25) – 7 mg, magnesium stearate – 1,5 mg.

Description: tablets of white or white with a creamy tint color, flat-cylindrical with a bevel.

Pharmacotherapeutic group: anxiolytic agent (tranquilizer).

Afobazole® is a selective non-benzodiazepine anxiolytic.

Acting on sigma-1 receptors in brain nerve cells, Afobazole® stabilizes GABA / benzodiazepine receptors and restores their sensitivity to endogenous inhibitory mediators. Afobazole® also increases the bioenergetic potential of neurons and has a neuroprotective effect: restores and protects nerve cells.

The action of the drug is implemented mainly in the form of a combination of anxiolytic (anti-anxiety) and mild stimulating (activating) effects. Afobazole® reduces or eliminates feelings of anxiety (preoccupation, bad feelings, apprehensions), irritability, tension (timidity, tearfulness, anxiety, inability to relax, insomnia, fear), depressed mood, somatic manifestations of anxiety (muscle, sensory, cardiovascular, respiratory, gastrointestinal symptoms), autonomic disorders (dry mouth, sweating, dizziness), cognitive impairment (difficulty concentrating, impaired memory), including

The effect of the drug develops on the 5-7th day of treatment. The maximum effect is achieved by the end of 4 weeks of treatment and persists after an average of 1-2 weeks after treatment.

Afobazol® does not cause muscle weakness, drowsiness, and does not have a negative effect on concentration and memory. With its use, addiction, drug dependence does not form, and the “withdrawal” syndrome does not develop.

After oral administration, Afobazole® is well and rapidly absorbed from the gastrointestinal tract.

The maximum concentration of the drug in plasma (Cmax) is 0,130 0,073 mcg / ml; time to reach maximum concentration (Tmax) – 0,85 0,13 hours

Metabolism: Afobazole® undergoes a “first pass effect” through the liver, the main areas of metabolism are hydroxylation on the aromatic ring of the benzimidazole ring and oxidation on the morpholine fragment.

Afobazole® is intensively distributed over well-vascularized organs, it is characterized by rapid transfer from the central pool (blood plasma) to the peripheral (highly vascularized organs and tissues).

The half-life of Afobazole® when administered orally is 0,82 0,54 hours. The short half-life is due to the intensive biotransformation of the drug and the rapid distribution from blood plasma to organs and tissues. The drug is excreted mainly in the form of metabolites and partially unchanged with urine and feces.

Indications for use

Arterial hypertension. Angina pectoris. Acute myocardial infarction (with stable hemodynamics). Tachycardia: sinus. Atrial Ventricular. Paroxysmal and so on; Extrasystole. Atrial flutter and flickering. Hyperkinetic cardiac syndrome. Mitral valve prolapse. Hypertensive neurocirculatory dystonia; complex therapy of hypertrophic cardiomyopathy. Pheochromocytomas. Thyrotoxicosis. Essential tremor; migraine (prevention).

Hypersensitivity, sinus bradycardia (heart rate less than 50 beats / min), sinoatrial blockade, sinus node weakness syndrome, AV block II – III degree, arterial hypotension (with arterial pressure less than 90 mm), acute or chronic heart failure in the decompensation stage, cardiogenic shock, peripheral circulation disorder, pregnancy, breast-feeding.

Afobazole® is used in adults with anxiety conditions: generalized anxiety disorders, neurasthenia, adaptation disorders, in patients with various somatic diseases (bronchial asthma, irritable bowel syndrome, systemic lupus erythematosus, coronary heart disease, hypertension, arrhythmias), dermatological, oncological and other diseases.

Individual intolerance to the drug. Galactose intolerance, lactase deficiency or glucose-galactose malabsorption. Pregnancy, lactation. Children under 18 years old.

Nosology

• E05,9 Thyrotoxicosis, unspecified. • G25,0 Essential tremor. • G43 Migraine. • I10 Essential (primary) hypertension. • I15 Secondary hypertension. • I20 Angina pectoris [angina pectoris]. • I20,0 Unstable angina pectoris. • I21 Acute myocardial infarction. • I25 Chronic ischemic heart disease. • I25,2 Past myocardial infarction.

• I27 Other forms of pulmonary heart disease. • I34,1 Mitral valve prolapse. • I42 Cardiomyopathy. • I47,1 Supraventricular tachycardia. • I47,2 Ventricular tachycardia. • I48 Atrial fibrillation and flutter. • I49,4 Other and unspecified premature depolarization. • I49,9 Unspecified heart rhythm disorder. • R07,2 Pain in the region of the heart.

Substance characteristics

Crystalline powder. Soluble in water (26,5 mg / ml at 37 ° C), good in 1M hydrochloric acid solution (300 mg / ml at 25 ° C) and poorly in chloroform (3 mg / ml at temperature 25 ° C).

We compared and appreciated that Afobazol or its main competitor analogues are better – Tenoten, Persen, Phenazepam, Novopassit and some others in certain conditions.

Comparative characteristics are presented below:

  1. Tenoten and Afobazole have similar properties. Both drugs belong to the group of tranquilizers, which have anxiolytic, anticonvulsant, muscle relaxant, sedative effects. The drug Tenoten is prescribed during conditions after cerebrovascular accident due to intoxication and oxygen starvation. The tool has a neuroprotective effect, leads to a decrease in the number of damaged brain cells. Tenoten, unlike Afobazole, is approved for children and adults. And Afobazol is allowed only from the age of 18.
  2. Persen. Both drugs are tranquilizers with sedative effects. Their action is aimed at relieving stress, nervous state, fatigue, irritability. In addition, they normalize brain activity, improve mental abilities, increase memory and blood circulation of the brain. Unlike Afobazol, Persen consists only of natural plant components, and therefore its effect is not so strong. Also, the scope of Afobazole is much wider. Persen is prescribed to eliminate increased irritability, irritability, and with insomnia. With disorders of the nervous system, the use of the drug will be ineffective.
  3. Afobazole and Phenazepam. These drugs are part of the group of tranquilizers. Phenazepam also has a sedative effect. Quickly relieves irritability, nervousness, irritation, fatigue, helps with sleep disorders. Eliminates autonomic disorders such as dizziness, headache, excessive sweating, muscle twitching and other symptoms. The difference between Phenazepam and Afobazole is in price. The cost of one package of the first for 20 tablets in a pharmacy is 120 rubles, when the cost of a package of Afobazole is 360-400 rubles and above. But unlike Afobazole, Phenazepam has many contraindications.
  4. Novopassit and Afobozol have similar properties. Both drugs eliminate irritation, fatigue, sleep disturbances, tension, headaches and other unpleasant neuralgic problems. Novopassit consists only of natural components, so it can only eliminate mild disorders. Usually it is prescribed during premenstrual syndrome, with menopause, with headaches, myasthenia gravis, migraines. Which of these drugs can only be determined better by the doctor, since both drugs are aimed at eliminating various neuralgic disorders.
  5. Grandaxinum. Both drugs have the same effects – reduce stress, irritation, relieve neurosis, sleep disturbances, headaches and other disorders. If you compare which of these means is better, then we can say that the drug Grandaxin acts much softer, it is allowed for pregnant women in the 1st and 2nd trimester, but has many side effects. In addition, unlike Afobozal, Grandexin has a high cost, for one package the price is almost 800 rubles.
  6. Phenibut refers to nootropic drugs that are derived from gamma-aminobutyric acid. This drug quickly eliminates fatigue, increases mental ability, relieves stress and enhances performance. In addition, the drug is non-toxic and absolutely safe for the body. Its excretion from the body occurs 3 hours after administration. However, unlike Afobazole, this remedy is worse tolerated by the body and causes many side effects. If we talk about the cost, Phenibut is cheaper than Afobazole, the cost of one package is 120-140 rubles.
  7. Adaptol as well as Afobazole relieves fatigue, tension, irritability, helps with sleep disorders. In addition, it eliminates various sedative disorders – headaches, dizziness, migraine, sweating, muscle twitching. It has a mild sedative effect. Many patient reviews indicate that the drug has a quick effect and is not addictive. But compared with Afobazole, this drug has a weak effect.

With the combined use of Afobazole with nootropics and tranquilizers, the drug has the most pronounced effect. It can be taken simultaneously with Novopassit, Persen, Phenazipam, Adapol, Tenoten and many other tranquilizers.

In any case, the dosage and course of administration should be prescribed by the attending physician.

Dosing and Administration

The optimal single dose is 10 mg; daily allowance – 30 mg, distributed in 3 doses throughout the day. The duration of the course of the drug is 2-4 weeks.

If necessary, on the recommendation of a doctor, the daily dose of the drug can be increased to 60 mg, and the duration of treatment up to 3 months.

The drug does not adversely affect the driving of vehicles and the performance of potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

Interaction

Allergic reactions are possible.

Rarely, a headache that usually goes away on its own and does not require discontinuation of the drug.

Afobazole® does not interact with ethanol and does not affect the hypnotic effect of thiopental. Enhances the anticonvulsant effect of carbamazepine. It causes an increase in the anxiolytic effect of diazepam.

From the nervous system and sensory organs. Fatigue. Weakness. Dizziness. Headache. Drowsiness or insomnia. Nightmares. Depression. Anxiety. Confusion or short-term memory loss. Hallucinations. Weakening reactivity. Paresthesia Cramps visual impairment.

Decreased secretion of saliva and tear fluid. Conjunctivitis. From the cardiovascular system and blood (hematopoiesis. Hemostasis): bradycardia. Heartbeat Violation of myocardial conduction. AV block. Arrhythmias. Weakening myocardial contractility. Heart failure. Hypotension. Syncope. Raynaud’s phenomenon. Vasculitis. Chest pain.

Thrombocytopenia. Agranulocytosis. From the digestive tract. Dry mouth, nausea, vomiting, abdominal pain, diarrhea, constipation, impaired liver function. From the respiratory system. Shortness of breath, laryngo – and bronchospasm. Allergic reactions. Itching, rash, erythema, urticaria, psoriasis-like and dystrophic skin changes. Other.

Antiarrhythmic and anesthetic drugs enhance cardiodepressive effect (the risk of developing bradycardia, arrhythmias, hypotension, heart failure). Reserpine, methyldopa, clonidine, guanfacine, cardiac glycosides potentiate the negative chrono-, dromo- and batmotropic effect, insulin and other antidiabetic agents – hypoglycemia.

NSAIDs, estrogens, sympathomimetics, xanthines weaken the hypotensive effect, absorption, increase – sympatholytics, nitroglycerin, hydralazine and other antihypertensive drugs, antacids – slow down absorption. Cimetidine inhibits metabolism. It prolongs the action of antidepolarizing muscle relaxants, the anticoagulant effect of coumarins.

How does the drug affect the body? First of all, this tool stabilizes the nerve endings, restoring their sensitivity, normalizes the VSD.

Basically, the drug has an anti-anxiety and stimulating effect. The main indications for use are: reducing or neutralizing the state of anxiety, tension, somatic consequences of the anxiety state, disorders in the autonomic system and cognitive disorders. The first effects are already noticeable after 7 days of administration, and the maximum can be achieved in a month. Moreover, after the end of the course of treatment, the result is saved for a couple of weeks (which analogues rarely guarantee).

Despite the calming function, it does not cause drowsiness and does not adversely affect the state of attention and memory.

So, the main advantages of the drug:

  • does not affect memory and attention (like its analogues);
  • reduces the degree of psychological discomfort;
  • exhibits a stimulating and anti-anxiety effect;
  • the readings of the IRR are improved;
  • does not suppress consciousness;
  • focuses and improves memory.

Overdose

With a significant overdose and intoxication, it is possible to develop a sedative effect and increased drowsiness without manifestations of muscle relaxation. As an emergency, caffeine 20% solution in ampoules of 1,0 ml 2-3 times a day subcutaneously is used.

Symptoms Bradycardia, AV – blockade II – III degree, heart failure, respiratory failure, hypotension, bronchospasm, hypoglycemia. Treatment. Gastric lavage and the appointment of adsorbing agents; symptomatic therapy is atropine. Isoprenaline. Orciprenaline. Cardiac glycosides or glucagon. Diuretics.

When is it taken and compatible with other medicines?

This drug is intended exclusively for adults and is prescribed for certain ailments.

  • neurasthenia, anxiety and adaptive disorders;
  • PMS, insomnia, VSD;
  • hypertension, asthma, ischemic disease, lupus erythematosus;
  • arrhythmia, bronchial asthma;
  • treatment of alcohol syndrome.

In addition, it is recommended to take to improve memory.

PreparationThe effect produced by Afobazole
DiazepamPerfectly complements
CarbamazepineIncreases anticonvulsant effect
Thiopental, EthanolDoes not interfere with hypnotic and narcotic effects

As you can see, the drug was widely used in cases where a person is not able to cope with daily stressful situations that accumulate day by day.

Application Precautions

Treatment is carried out with regular medical supervision. Before starting therapy, heart failure should be compensated. During treatment, monitoring of heart rate, blood pressure, blood glucose level (dose adjustment of antidiabetic drugs is possible) and monitoring of the appearance of symptoms of heart failure are necessary.

Use with caution while working for drivers of vehicles and people whose profession is associated with increased concentration of attention. At the time of therapy, it is recommended to exclude alcohol. In patients with diabetes mellitus and hyperthyroidism, it can mask tachycardia caused by hypoglycemia or thyrotoxicosis.

With pheochromocytoma, alpha-adrenolytics should be used simultaneously. It is possible to increase the severity of the hypersensitivity reaction and the lack of effect of the usual doses of epinephrine against the background of a burdened allergic history. In the case of the appearance of increasing bradycardia in elderly patients (less than 50 beats.

/ min), hypotension (with arterial pressure below 100 mm), AV block, bronchospasm, ventricular arrhythmias, severe liver and kidney dysfunctions, it is necessary to reduce the dose or stop treatment. The therapy should be discontinued gradually, reducing the dose, within 10-14 days. Patients with coronary heart disease should be closely monitored during the period of drug withdrawal.

Detonic – a unique medicine that helps fight hypertension at all stages of its development.

Detonic for pressure normalization

The complex effect of plant components of the drug Detonic on the walls of blood vessels and the autonomic nervous system contribute to a rapid decrease in blood pressure. In addition, this drug prevents the development of atherosclerosis, thanks to the unique components that are involved in the synthesis of lecithin, an amino acid that regulates cholesterol metabolism and prevents the formation of atherosclerotic plaques.

Detonic not addictive and withdrawal syndrome, since all components of the product are natural.

Detailed information about Detonic is located on the manufacturer’s page www.detonicnd.com.

Perhaps you want to know about the new medication - Cardiol, which perfectly normalizes blood pressure. Cardiol capsules are an excellent tool for the prevention of many heart diseases, because they contain unique components. This drug is superior in its therapeutic properties to such drugs: Cardiline, Recardio, Detonic. If you want to know detailed information about Cardiol, go to the manufacturer’s website.There you will find answers to questions related to the use of this drug, customer reviews and doctors. You can also find out the Cardiol capsules in your country and the delivery conditions. Some people manage to get a 50% discount on the purchase of this drug (how to do this and buy pills for the treatment of hypertension for 39 euros is written on the official website of the manufacturer.)Cardiol capsules for heart
Svetlana Borszavich

General practitioner, cardiologist, with active work in therapy, gastroenterology, cardiology, rheumatology, immunology with allergology.
Fluent in general clinical methods for the diagnosis and treatment of heart disease, as well as electrocardiography, echocardiography, monitoring of cholera on an ECG and daily monitoring of blood pressure.
The treatment complex developed by the author significantly helps with cerebrovascular injuries and metabolic disorders in the brain and vascular diseases: hypertension and complications caused by diabetes.
The author is a member of the European Society of Therapists, a regular participant in scientific conferences and congresses in the field of cardiology and general medicine. She has repeatedly participated in a research program at a private university in Japan in the field of reconstructive medicine.

Detonic